Skip to header Skip to main navigation Skip to main content Skip to footer
Home
Academic Citations from Palestine
Foregrounding the Research of Academics in Palestine

Main navigation

  • Home
  • Search
  • About

Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Blank
Al-Azhar University – Gaza
Jaber F.; Ayyad M.; Alsakarneh S.; Alsharaeh T.; Salahat A.-J.; Jaber M.; Gangwani M.K.; Abboud Y.; Mohamed I.; Ali H.; Kilani Y.; Farraye F.A.; Hashash J.G.
Jaber, Fouad (57927659200); Ayyad, Mohammed (57226576955); Alsakarneh, Saqr (57919358400); Alsharaeh, Tala (58791721900); Salahat, Ahmed-Jordan (58791133800); Jaber, Mohammad (58774780400); Gangwani, Manesh Kumar (57196117639); Abboud, Yazan (57224812811); Mohamed, Islam (58299799300); Ali, Hassam (57221081047); Kilani, Yassine (57556786600); Farraye, Francis A. (35586182900); Hashash, Jana G. (16836619200)
57927659200; 57226576955; 57919358400; 58791721900; 58791133800; 58774780400; 57196117639; 57224812811; 58299799300; 57221081047; 57556786600; 35586182900; 16836619200
2024
American Journal of Therapeutics
Efficacy and Safety of Interleukin-12/23 and Interleukin-23 Inhibitors for Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
32
1
e17
e29
Lippincott Williams and Wilkins
Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States; Faculty of Medicine, Al-Quds University, Jerusalem, Palestine; Department of Medicine, The University of Jordan, Faculty of Medicine, Amman, Jordan; Department of Medicine, Al-Azhar University, Faculty of Medicine, Gaza, Palestine; Department of Internal Medicine, University of Toledo, Toledo, OH, United States; Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States; Department of Gastroenterology, ECU Health Medical Center, Greenville, NC, United States; Department of Internal Medicine, NYC Health + Hospitals | Lincoln, Weill Cornell Medical College, Bronx, NY, United States; Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States
Jaber F., Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States; Ayyad M., Faculty of Medicine, Al-Quds University, Jerusalem, Palestine; Alsakarneh S., Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States; Alsharaeh T., Department of Medicine, The University of Jordan, Faculty of Medicine, Amman, Jordan; Salahat A.-J., Department of Medicine, The University of Jordan, Faculty of Medicine, Amman, Jordan; Jaber M., Department of Medicine, Al-Azhar University, Faculty of Medicine, Gaza, Palestine; Gangwani M.K., Department of Internal Medicine, University of Toledo, Toledo, OH, United States; Abboud Y., Department of Internal Medicine, Rutgers New Jersey Medical School, Newark, NJ, United States; Mohamed I., Department of Medicine, University of Missouri-Kansas City, Kansas City, MO, United States; Ali H., Department of Gastroenterology, ECU Health Medical Center, Greenville, NC, United States; Kilani Y., Department of Internal Medicine, NYC Health + Hospitals | Lincoln, Weill Cornell Medical College, Bronx, NY, United States; Farraye F.A., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States; Hashash J.G., Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, United States
F. Jaber; Department of Medicine, University of Missouri-Kansas City, Kansas City, 5000 Holmes St, 64108, United States; email: fouad.jaber.md@gmail.com
3
10.1097/MJT.0000000000001766
inflammatory bowel disease; interleukin-23 inhibitors; meta-analysis; ulcerative colitis
Colitis, Ulcerative; Humans; Interleukin-12; Interleukin-23; Interleukin-23 Subunit p19; Randomized Controlled Trials as Topic; Remission Induction; Severity of Illness Index; Treatment Outcome; aminosalicylic acid; corticosteroid; cytokine receptor antagonist; golimumab; guselkumab; immunosuppressive agent; interleukin 12; interleukin 12p40; interleukin 23; interleukin 23p19; mirikizumab; placebo; ustekinumab; interleukin 12; interleukin 23; interleukin 23p19; adult; anemia; arthralgia; Article; Cochrane Library; disease severity; drug efficacy; drug safety; drug withdrawal; Embase; female; gastrointestinal endoscopy; headache; histology; human; infection; injection site reaction; maintenance therapy; male; Medline; meta analysis; opportunistic infection; outcome assessment; patient-reported outcome; randomized controlled trial (topic); remission; rhinopharyngitis; risk reduction; Scopus; systematic review; treatment response; ulcerative colitis; upper respiratory tract infection; drug therapy; immunology; procedures; randomized controlled trial (topic); severity of illness index; treatment outcome; ulcerative colitis